T. Rowe Price Associates, Inc. 13D and 13G filings for Acceleron Pharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-16 12:23 pm Purchase | 2020-12-31 | 13G | Acceleron Pharma Inc. XLRN | T. Rowe Price Associates, Inc. | 5,309,766 8.800% | 1,877,023 (+54.68%) | Filing |
| 2020-02-14 1:30 pm Purchase | 2019-12-31 | 13G | Acceleron Pharma Inc. XLRN | T. Rowe Price Associates, Inc. | 3,432,743 6.400% | 453,857 (+15.24%) | Filing |